2025-2034 Contraceptive Devices Market Roadmap: Insights for Competitive Advantage

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Contraceptive Devices Market Size By 2025?
Recent years have seen robust growth in the market size of contraceptive devices. The market, which stood at $12.8 billion in 2024, is projected to expand to $13.55 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.9%. This growth trajectory in the previous period can be traced back to the rising awareness of family planning and contraceptive techniques, governmental initiatives, global population growth, a heightened emphasis on women's health and empowerment, as well as improved healthcare access.

How Big Is the Contraceptive Devices Market Size Expected to Grow by 2029?
The contraceptive devices market is projected to experience substantial expansion in the forthcoming years. It is predicted to increase to $17.25 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth over this period can be attributed to factors such as heightened awareness about sexual health and protection against STDs, the economic advantages of managing family size, the increasing cultural acceptance of contraception, a high percentage of the young population within reproductive age, and the role of social media in promoting awareness. Key trends expected during this forecast period comprise advances in contraceptive technologies, awareness campaigns conducted by NGOs and health organizations, advancements in pharmaceutical formulation, availability of an extensive array of contraceptive products, and investments in the research and development of new contraceptive methods.

View the full report here:
https://www.thebusinessresearchcompany.com/report/contraceptive-devices-global-market-report

Which Key Market Drivers Powering Contraceptive Devices Market Expansion and Growth?
The surge in sexually transmitted diseases is projected to fuel the expansion of the contraceptive device market. These diseases, primarily spread through sexual contact, can affect different body parts and potentially result in various symptoms and health issues. The rise in these diseases can be attributed to factors such as increased sexual activity, inadequate protection, lack of proper sexual health education, and difficulties in accessing healthcare and testing services. Contraceptive devices, particularly condoms, are indispensable in preventing sexually transmitted diseases as they create a barrier preventing the transfer of infectious fluids and lesions. For example, a report from the UK Health Security Agency, a government organization based in the UK, reported in July 2024 that the number of new STI diagnoses in England for 2023 was 401,800, showing a 4.7% increase from 383,789 cases in 2022. Diagnoses of gonorrhea increased by 7.5% from 79,268 in 2022 to 85,223 in 2023. Simultaneously, there was a 9.4% increase in infectious syphilis diagnoses, with figures going from 8,693 in 2022 to 9,513 in 2023. Consequently, the escalating incidence of sexually transmitted diseases is spearheading the growth of the contraceptive device market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18320&type=smp

Which Emerging Trends Are Transforming the Contraceptive Devices Market in 2025?
Leading corporations in the contraceptive device market are advancing with the creation of new products such as contraceptive vaginal rings. These innovative products offer a simple, easy-to-maintain birth control method that only needs to be inserted once a month. The contraceptive vaginal ring is a flexible device that releases hormones into the vagina to prevent pregnancy by obstructing ovulation and increasing the thickness of the cervical mucus. An example of this is the EnilloRing launched by Xiromed LLC, a pharmaceuticals company from the USA, in October 2023. The EnilloRing produced by Xiromed combines etonogestrel and ethinyl estradiol, and is deigned for long-term usage, remaining in place for a period of three weeks. After these three weeks, there's a one-week interval when the ring is removed, providing effective prevention of pregnancy.

What Are the Emerging Segments in the Contraceptive Devices Market?
The contraceptive devices market covered in this report is segmented -

1) By Product Type: Male Contraceptive Devices, Female Contraceptive Devices, Female Condoms, Diaphragms And Sponges, Vaginal Rings, Intrauterine Devices, Sub-Dermal Implants, Others Product Types
2) By Technology: Hormonal Contraceptives, Barrier Contraceptives
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channels, Public Channel And Non-Governmental Organization (NGO), Other Distribution Channels

Subsegments:
1) By Male Contraceptive Devices: Male Condoms, Vasectomy Devices, Male Contraceptive Injections, Male Contraceptive Pills
2) By Female Contraceptive Devices: Female Condoms, Diaphragms And Sponges, Vaginal Rings, Intrauterine Devices (IUDs), Sub-Dermal Implants, Emergency Contraceptive Devices
3) By Female Condoms: Internal Latex Female Condoms, Non-Latex Female Condoms
4) By Diaphragms And Sponges: Silicone Diaphragms, Latex Diaphragms, Contraceptive Sponges
5) By Vaginal Rings: NuvaRing (And Other Hormonal Vaginal Rings), Non-Hormonal Vaginal Rings
6) By Intrauterine Devices (IUDs): Copper IUDs, Hormonal IUDs, Non-Hormonal IUDs
7) By Sub-Dermal Implants: Hormonal Implants, Non-Hormonal Implants
8) By Other Product Types: Contraceptive Patches, Contraceptive Injections, Contraceptive Pills, Contraceptive Gel And Creams

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18320&type=smp

Who Are the Global Leaders in the Contraceptive Devices Market?
Major companies operating in the contraceptive devices market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Boehringer Ingelheim International GmbH., Teva Pharmaceutical Industries Ltd., Mylan N.V., Organon Group, Hologic Inc., CooperSurgical Inc., Cipla Inc., Mankind Pharma Ltd., TTK HealthCare Ltd., Zondervan, Merck Sharp & Dohme Corp., Evofem Biosciences Inc., Veru Inc., Medisafe Inc., Agile Therapeutics Inc., Janssen Global Services LLC, HLL Lifecare Ltd., Mayer Laboratories Inc., V-Care Pharma Pvt. Ltd., Vardhaman Lifecare Pvt. Ltd., Actavis Pharma LLC, Pregna International Limited

Which are the Top Profitable Regional Markets for the Contraceptive Devices Industry?
North America was the largest region in the contraceptive devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the contraceptive devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18320

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.